Johnson & Johnson (JNJ) announces FDA approval of icotyde (icotrokinra) ushers in new Era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Importance
Level 1
- Met all primary efficacy endpoints in four phase 3 studies with 2,500 patients.
- Adverse reactions for icotyde within 1.1% of placebo through week 16; no new safety signals through week 52.
#JOHNSON & JOHNSON#JNJ.US#ERA GROUP INC#FDA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES